Table 6 Association between modified PRACTICAL risk score and prostate cancer metastasis or death in both the VIP and MDC cohorts on univariate analysis and adjusted for total PSA and 4kscore among PSA subgroups.
From: Prostate cancer polygenic risk score and prediction of lethal prostate cancer
Modifieda PRACTICAL risk only | Modified PRACTICAL risk + total PSA | Modified PRACTICAL risk + 4Kscore | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
PSA range | Total N | Case N | ORb | 95% CI | p value | ORb | 95% CI | p value | ORb | 95% CI | p value |
PSA ≥ 0 | 1991 | 475 | 1.07 | 1.05, 1.08 | <0.001 | 1.04 | 1.03, 1.06 | <0.001 | 1.05 | 1.03, 1.06 | <0.001 |
PSA ≤ 1 | 722 | 46 | 1.05 | 1.01, 1.10 | 0.026 | 1.05 | 1.00, 1.09 | 0.034 | 1.05 | 1.00, 1.09 | 0.029 |
PSA ≥ 1 | 1278 | 433 | 1.05 | 1.03, 1.07 | <0.001 | 1.04 | 1.02, 1.06 | <0.001 | 1.03 | 1.02, 1.05 | <0.001 |
PSA ≥ 2 | 754 | 336 | 1.04 | 1.02, 1.06 | <0.001 | 1.03 | 1.01, 1.05 | 0.009 | 1.02 | 1.00, 1.04 | 0.047 |
PSA ≥ 3 | 506 | 249 | 1.05 | 1.02, 1.07 | <0.001 | 1.04 | 1.01, 1.07 | 0.004 | 1.03 | 1.00, 1.06 | 0.023 |
PSA ≥ 4 | 363 | 202 | 1.05 | 1.02, 1.08 | 0.003 | 1.04 | 1.01, 1.08 | 0.008 | 1.03 | 1.00, 1.07 | 0.045 |
